Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax
Primaquine, an 8-aminoquinoline, is the only medication approved by the World Health Organization to treat the hypnozoite stage of Plasmodium vivax and P. ovale malaria. Relapse, triggered by activation of dormant hypnozoites in the liver, can occur weeks to years after primary infection, and provid...
Guardado en:
Autores principales: | Alexandra G. A. Stewart, Peter A. Zimmerman, James S. McCarthy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bcdae92ec9de4d6b8ac6fb0e2b29e11b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics
por: Isabelle Austin-Zimmerman, et al.
Publicado: (2021) -
Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives
por: Markus MB
Publicado: (2021) -
Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China
por: Ying Dong, et al.
Publicado: (2021) -
Clinical and epidemiological characterization of severe Plasmodium vivax malaria in Gujarat, India
por: Anupkumar R. Anvikar, et al.
Publicado: (2020) -
Malaria por Plasmodium vivax y falla al tratamiento radical
por: García,Julián, et al.
Publicado: (2016)